Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
80 Results for "
AD model
" in MedChemExpress (MCE) Product Catalog:
Products (80)
80 Results for "AD model" in MCE Product Catalog:
Cat. No.: HY-161953
Target:
Research Areas:
O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects .
Cat. No.: HY-148807C
CAS No.: 2908753-07-9
Synonyms: QC8222 sodium; TACH 101 sodium
Target:
Research Areas:
Zavondemstat (QC8222; TACH 101) sodium is an orally active pan-KDM4 inhibitor, with a IC50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat sodium induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat sodium suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat sodium can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .
Cat. No.: HY-163909
Target:
Research Areas:
AChE-IN-72 (Compound 13a) is an inhibitor for acetylcholinesterase (AChE) with an IC50 of 0.59 μM. AChE-IN-72 inhibits BChE with an IC50 of 5.02 μM. AChE-IN-72 exhibits radical scavenging with IC50 of 5.88 μM. AChE-IN-72 exhibits iron-chelating property, inhibits Aβ1−42 aggregation, and inhibits NLRP3 inflammasome activation. AChE-IN-72 ameliorates memory impairment in Betaine (HY-B0710)-induced AD mouse model. AChE-IN-72 is blood-brain barrier (BBB) penetrable .
Cat. No.: HY-166014
CAS No.: 87092-34-0
Target:
Research Areas:
11,14-Eicosadienoate sodium is an unsaturated fatty acid that can serve as a biomarker for Alzheimer's disease. 11,14-Eicosadienoate sodium is downregulated in the feces and upregulated in the hippocampus of Alzheimer's disease model mice. 11,14-Eicosadienoate sodium can be used for research on Alzheimer's disease .
Cat. No.: HY-173152
Target:
Research Areas:
AChE/BChE-IN-26 (Compound 20aa) is a cholinesterase inhibitor with IC50 values of 0.75 μM and 4.11 μM against eeAChE and eqBChE, respectively. AChE/BChE-IN-26 has antioxidant activity and can be used in the research of diseases such as Alzheimer's disease .
Cat. No.: HY-117710A
CAS No.: 1531586-58-9
Research Areas:
AD-35 free base is an orally active, blood-brain barrier-permeable acetylcholinesterase inhibitor with an IC50 of 793 nM. AD-35 free base inhibits metal-induced amyloid-β aggregation and disassembles preformed amyloid-β aggregates. In rat models of cognitive impairment, AD-35 free base attenuates Aβ25-35-induced astrocyte activation, TNF-α and IL-1β release, inhibits ERK phosphorylation, and alleviates learning and memory deficits. AD-35 free base can be used for research on Alzheimer's disease .
Cat. No.: HY-189262
Research Areas:
Multitarget AD-IN-8 is a blood-brain barrier-penetrant, orally active multitarget inhibitor. Multitarget AD-IN-8 inhibits abnormal Tau phosphorylation at Thr181 and Ser396 sites and attenuates NF-κB phosphorylation. Multitarget AD-IN-8 downregulates BACE1 expression to reduce Aβ production, inhibits the Bax/Bcl-2 pathway, and suppresses Caspase-1 activation. Multitarget AD-IN-8 attenuates p38, ERK1/2, and JNK phosphorylation and inhibits Aβ25-35-induced Apoptosis. Multitarget AD-IN-8 exhibits neuroprotective effects against Aβ25-35-induced injury, ameliorates learning and memory deficits in AD mouse models, and alleviates hippocampal neuronal pathological damage. Multitarget AD-IN-8 can be used for research on Alzheimer's disease .
Cat. No.: HY-180891
Target:
Research Areas:
Multitarget AD-IN-4 (compound IIIj) is a multitarget-directed ligand (MTDL), with the ability to simultaneously inhibit ChE enzymes (EeAChE IC50 = 0.157 μM, eqBuChE IC50 = 0.147 μM, hAChE IC50 = 1.551 μM, hBuChE IC50 = 2.152 μM), exhibit antioxidant activity, provide neuroprotection, and inhibit calcium channels (Ca 2+ channel blockade: IC50 = 30.59 μM). Multitarget AD-IN-4 reverses Scopolamine (HY-N0296)-induced amnesia in a mouse model. Multitarget AD-IN-4 can be used for Alzheimer’s disease (AD) research .
Cat. No.: HY-170976
Target:
Research Areas:
BuChE-IN-16 (Compound 6a) is an orally active, BBB-permeable, and selective BuChE inhibitor with an IC50 of 0.33 μM. BuChE-IN-16 has anti-inflammatory and neuroprotective effects. BuChE-IN-16 can improve the cognitive function of zebrafish with Alzheimer's disease (AD) and alleviate memory impairment in mice induced by Scopolamine (HY-N0296). BuChE-IN-16 can be used for the research of AD .
Cat. No.: HY-11013R
CAS No.: 887603-94-3
Synonyms: ST-101 (Standard)
Target:
Research Areas:
ZSET1446 (Standard) is the analytical standard of ZSET1446 (HY-11013). This product is intended for research and analytical applications. ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.
Cat. No.: HY-D2967
Cat. No.: HY-P11677
Research Areas:
Cat. No.: HY-176036A
Target:
Research Areas:
MS1262 TFA is a blood-brain barrier-permeable, selective inhibitor of histone methyltransferases G9a (EHMT2) and GLP (EHMT1), with an IC50 of 19 nM and a Kd of 74 nM against G9a, and an IC50 of 6 nM and a Kd of 19 nM against GLP. MS1262 TFA reduces the dimethylation level of histone H3 lysine 9 and decreases the size of Aβ plaques. MS1262 TFA restores hippocampal long-term potentiation (LTP) and miniature excitatory postsynaptic current (sEPSC) frequency, ameliorates spatial memory deficits, and reverses anxiety-like and depression-like behaviors in AD model mice. MS1262 TFA reverses the expression/phosphorylation levels of early AD biomarkers, providing support for stage-specific diagnosis of AD. MS1262 TFA reduces the risk of thrombus rupture. MS1262 TFA can be used in research related to Alzheimer's disease, colorectal cancer, and triple-negative breast cancer .
Cat. No.: HY-184919
CAS No.: 3056058-96-6
Target:
Research Areas:
LMP2-IN-1 is an orally bioavailable, brain-permeable macrocyclic peptide epoxyketone, acts as a selective and irreversible inhibitor of LMP2 (IC50 = 87 nM). LMP2-IN-1 rapidly distributes to the brain and forms an irreversible LMP2:AR-01 adduct. LMP2-IN-1 improves memory function and rescues reactive astrocytes in 5xFAD mouse models of Alzheimer's disease (AD) .
Cat. No.: HY-178395S
Cat. No.: HY-W746542
CAS No.: 2732915-45-4
Cat. No.: HY-181576
CAS No.: 3115784-59-0
Target:
Research Areas:
ROCK2-IN-14 is an orally active, selective ROCK2 inhibitor (IC50=4.8 nM) with 212-fold selectivity over ROCK1 (IC50=1.01 μM). By inhibiting the ROCK2/S100A9 signaling pathway, ROCK2-IN-14 downregulates S100A9 expression, inhibits NM2 phosphorylation and restores cytoskeletal abnormalities. Furthermore, ROCK2-IN-14 reduces inflammatory cytokine levels, alleviates skin inflammation and exerts anti-inflammatory activity. ROCK2-IN-14 also significantly inhibits ear thickening in a mouse model of atopic dermatitis (AD), and decreases the levels of IgE, TNF-α, IL-6 and TSLP. ROCK2-IN-14 can be used for research on atopic dermatitis .
Cat. No.: HY-D3069
CAS No.: 2892545-08-1
Target:
Research Areas:
DNTPH is a near-infrared (NIR) aggregation-induced emission (AIE) fluorescent probe used for imaging β-amyloid (Aβ) aggregates. Designed by balancing hydrophobic and hydrophilic groups, DNTPH achieves selective binding to Aβ42 fibrils and generates a near-infrared fluorescent signal with high signal-to-noise ratio. Upon binding to Aβ42 fibrils, DNTPH exhibits enhanced fluorescence, while also inhibiting Aβ42 fibril formation, promoting fibril depolymerization, attenuating Aβ-induced neurotoxicity, and improving cognitive function in Alzheimer's disease (AD) mice. DNTPH can be used in Alzheimer's disease research .
Cat. No.: HY-184583
CAS No.: 3121876-09-0
Research Areas:
S27-1047 is a brain-penetrant, potent and selective BChE (eqBChE IC50 = 7.16 nM; hBChE IC50 = 296.10 nM) inhibitor and Nrf2 activator. S27-1047 can directly bind Keap1, disrupt Keap1-Nrf2 interaction (FP IC50 = 36.87 nM), enhance antioxidant enzyme expression and activate the GSH-GPX4 axis to inhibit Aβ-induced ferroptosis. S27-1047 can protect against oxidative stress and neuroinflammation. S27-1047 can be used in Alzheimer's disease research .
Cat. No.: HY-W283930
CAS No.: 132858-26-5
Research Areas:
YHV98-4 is a selective, blood-brain barrier-permeable Hv1 inhibitor with an IC50 of 0.7 μM. YHV98-4 reduces ROS production and restores the SHP-1-pAKT signaling pathway. YHV98-4 decreases the spread of hyperphosphorylated Tau protein. YHV98-4 alleviates inflammation and produces analgesic effects. YHV98-4 improves cognitive function in mouse models of Alzheimer's disease. YHV98-4 can be used in research related to inflammatory pain, neuropathic pain and Alzheimer's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
